TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24806623

Group type: EXPERIMENTAL
Intervention: Nasoenteric tube
Number of subjects: 42

Group type: COMPARATOR
Intervention: Jejunostomy
Number of subjects: 42
Study: 23115765

Group type: EXPERIMENTAL
Intervention: Drained group (primary closure with drain application)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Secondary closure group (open healing)
Number of subjects: 20
Study: 19912243

Group type: COMPARATOR
Intervention: MMI 30 mg
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: MMI 30 mg + KI
Number of subjects: 134

Group type: COMPARATOR
Intervention: MMI 15 mg
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: MMI 15 mg + KI
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Groups 1, 2, 3, and 4
Number of subjects: 134
Study: 17879223

Group type: EXPERIMENTAL
Intervention: email bulimia therapy (eBT)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: unsupported Self directed writing (SDW)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Waiting list control (WLC)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Beck depression inventory (BDI)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Bulimia investigatory test (BITE)
Number of subjects: 97
Study: 17012875

Group type: EXPERIMENTAL
Intervention: rDEN1Delta30 vaccine (10^3 pfu)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 14616413

Group type: EXPERIMENTAL
Intervention: Voriconazole (200 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10739846

Group type: EXPERIMENTAL
Intervention: Mannan-binding lectin concentration during pregnancy
Number of subjects: 14
Study: 8741449

Group type: EXPERIMENTAL
Intervention: Infusion cardioplegia with recirculation type circuit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single pass type cardioplegia circuit
Number of subjects: 0
Study: 1424618

Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg single dose)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3881303

Group type: EXPERIMENTAL
Intervention: 80% complex carbohydrates and 20% simple carbohydrates (80/20)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50% complex carbohydrates and 50% simple carbohydrates (50/50)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20% complex carbohydrates and 80% simple carbohydrates (20/80)
Number of subjects: 12

Group type: COMPARATOR
Intervention: All diets
Number of subjects: 12
Study: 31912285

Group type: EXPERIMENTAL
Intervention: Epiduroscopy with mechanical lysis of adhesions
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Epiduroscopy with mechanical lysis of adhesions and medication (methylprednisolone and hyaluronidase)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Epiduroscopy
Number of subjects: 79
Study: 31531963

Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade
Number of subjects: 52
Study: 28883722

Group type: EXPERIMENTAL
Intervention: Aclidinium/formoterol (AB/FF) 400/12 μg twice daily
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 26003121

Group type: EXPERIMENTAL
Intervention: Traffic Light Poster (TFP) intervention
Number of subjects: 58
Study: 23881929

Group type: EXPERIMENTAL
Intervention: Pazopanib (VEGF-targeted agent)
Number of subjects: 225
Study: 21241468

Group type: EXPERIMENTAL
Intervention: Topical ranibizumab (Lucentis®) eye drops (2 mg/ml) four times daily for 1 month
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (BSS 4x/d for 1 month)
Number of subjects: 5
Study: 19592748

Group type: EXPERIMENTAL
Intervention: VR group
Number of subjects: 45

Group type: COMPARATOR
Intervention: non-VR group
Number of subjects: 45

Group type: COMPARATOR
Intervention: waiting list group
Number of subjects: 45
Study: 17163260

Group type: EXPERIMENTAL
Intervention: Lornoxicam 24 mg on day 1 followed by 8 mg twice daily for 5 days
Number of subjects: 220

Group type: COMPARATOR
Intervention: Diclofenac potassium 150 mg on day 1 followed by 50 mg twice daily for 5 days
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 220

Group type: COMPARATOR
Intervention: Diclofenac potassium
Number of subjects: 220
Study: 12574810

Group type: EXPERIMENTAL
Intervention: Calculated-dose strategy (based on regression formula)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard-dose strategy (fixed at 5 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 90
Study: 10845831

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 352

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 352
Study: 9109105

Group type: EXPERIMENTAL
Intervention: Somatostatin (SRIF-14) 50 micrograms administered every hour between 2200 and 0100 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 1546915

Group type: EXPERIMENTAL
Intervention: Predictors of bacteremia (elevated temperature, low systolic blood pressure, low platelet count)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Predictors of gram-negative bacteremia (elevated temperature, low systolic blood pressure, low platelet count)
Number of subjects: 465
Study: 3935298

Group type: EXPERIMENTAL
Intervention: Incremental doses of nalbuphine administered approximately four hours after cardiopulmonary bypass
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline administered approximately four hours after cardiopulmonary bypass
Number of subjects: 20
Study: 31359800

Group type: EXPERIMENTAL
Intervention: Radiopaque cement
Number of subjects: 33

Group type: COMPARATOR
Intervention: Radiolucent cement
Number of subjects: 33
Study: 29735344

Group type: EXPERIMENTAL
Intervention: DBS-40 μs
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: DBS-60 μs
Number of subjects: 9

Group type: COMPARATOR
Intervention: DBS-OFF
Number of subjects: 9
Study: 29441995

Group type: EXPERIMENTAL
Intervention: S‐1 plus oxaliplatin (SOX) as perioperative chemotherapy (group A, 50 patients)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Postoperative adjuvant chemotherapy (group B, 52 patients)
Number of subjects: 102
Study: 25997014

Group type: EXPERIMENTAL
Intervention: Tobacco cessation pharmacotherapies (specifics not provided)
Number of subjects: 1301
Study: 23164226

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota 3 times daily for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group with standard medical therapy
Number of subjects: 30
Study: 21347648

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 694
Study: 18626520

Group type: EXPERIMENTAL
Intervention: Immunohistochemical staining of TTF-1
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Immunohistochemical staining of CK7
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Immunohistochemical staining of CK20
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Immunohistochemical staining of TTF-1, CK7, and CK20 in mesotheliomas
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Immunohistochemical staining of TTF-1 in metastatic tumors
Number of subjects: 43
Study: 16531939

Group type: EXPERIMENTAL
Intervention: Patient-delivered partner treatment (PDPT)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Booklet-enhanced partner referral (BEPR)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Standard partner referral (PR)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Cost comparison
Number of subjects: 463
Study: 12744878

Group type: EXPERIMENTAL
Intervention: PFP-3 vaccine
Number of subjects: 294

Group type: COMPARATOR
Intervention: Adjuvant-control
Number of subjects: 294
Study: 10586395

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg once daily for 9 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo once daily for 9 days
Number of subjects: 12
Study: 8738947

Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae infection
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Adequate antibiotic therapy
Number of subjects: 263
Study: 1662033

Group type: EXPERIMENTAL
Intervention: Sinorphan 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sinorphan 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sinorphan 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sinorphan (all doses)
Number of subjects: 12
Study: 7037047

Group type: EXPERIMENTAL
Intervention: 2% epinephrine (EPI)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.1% dipivalyl epinephrine (DPE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31617335

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg body weight) administered at 11 a.m. or 6 p.m. for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group) administered at 11 a.m. or 6 p.m. for 24 weeks
Number of subjects: 0
Study: 29657029

Group type: EXPERIMENTAL
Intervention: Pharmacologic administration of FGF21
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mice with normal FGF21 levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mice lacking FGF21
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FGF21
Number of subjects: 0
Study: 26891181

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Topiramate in rs2832407*CC genotype
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Topiramate in rs2832407*A-allele carriers
Number of subjects: 138
Study: 24262513

Group type: EXPERIMENTAL
Intervention: Corinthian Raisins (CR) consumption (36 g/d, replacing snacks with similar energy density twice daily)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Corinthian Raisins (CR) consumption (36 g/d)
Number of subjects: 48
Study: 22101624

Group type: EXPERIMENTAL
Intervention: Tezosentan (3 mg/h for 2-3 h)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 21053624

Group type: EXPERIMENTAL
Intervention: Acupuncture plus cupping
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional differentiation of symptoms and signs
Number of subjects: 92
Study: 17612054

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 0
Study: 16640173

Group type: EXPERIMENTAL
Intervention: Latest antihypertensive drugs
Number of subjects: 37000000

Group type: COMPARATOR
Intervention: Older blood pressure strategies
Number of subjects: 37000000
Study: 11937309

Group type: EXPERIMENTAL
Intervention: Computerised form-based reports
Number of subjects: 2042

Group type: COMPARATOR
Intervention: Conventional free text reporting
Number of subjects: 2042
Study: 10402687

Group type: EXPERIMENTAL
Intervention: High DSM‐III‐R avoidant personality pathology
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Avoidant beliefs
Number of subjects: 57

Group type: COMPARATOR
Intervention: Low DSM‐III‐R avoidant personality pathology
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Low self-esteem
Number of subjects: 57

Group type: COMPARATOR
Intervention: Social phobia and general personality pathology
Number of subjects: 57
Study: 7743798

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin dosing regimen compatible with home use: two drops of 0.3% ciprofloxacin every 4 h over a 24‐h period (Group 1)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin dosing regimen applied by a trained professional: two drops of Ciloxan every 15 min over a 4‐h period (Group 2)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin dosing regimen applied by a trained professional with corneas abraded (Group 3)
Number of subjects: 31
Study: 1903409

Group type: EXPERIMENTAL
Intervention: Oral nitroglycerin (0.6 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6168124

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg p.o/day for 5 days
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 68
Study: 31498919

Group type: EXPERIMENTAL
Intervention: RASB continuation
Number of subjects: 316

Group type: COMPARATOR
Intervention: RASB discontinuation
Number of subjects: 316

Group type: COMPARATOR
Intervention: Nonuse of RASB
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: RASB initiation
Number of subjects: 316
Study: 28659162

Group type: EXPERIMENTAL
Intervention: Acupuncture plus herbal medicine and health education
Number of subjects: 80

Group type: COMPARATOR
Intervention: Health education only
Number of subjects: 80
Study: 26497218

Group type: EXPERIMENTAL
Intervention: Brief psychoeducational group intervention for relatives (4 sessions lasting 90 to 120 min each)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 180
Study: 23427970

Group type: EXPERIMENTAL
Intervention: Left-handed curriculum (30-minute introductory video and 2-hour instructor-led training)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Right-handed curriculum (30-minute introductory video and 2-hour instructor-led training)
Number of subjects: 19
Study: 21273912

Group type: EXPERIMENTAL
Intervention: Circadian rhythm of cortisol (C) and testosterone (T)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0800 and 2000 hours testing sessions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Salivary testosterone (T) and cortisol (C) levels
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Taural
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Strength and power training or testing
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Session RPE
Number of subjects: 20
Study: 19324953

Group type: EXPERIMENTAL
Intervention: Cross-shift decrease in PEF of 5 L.min(‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serial PEF records analysis using linear discriminant analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mean work/rest day PEF comparison
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cross-shift changes in PEF
Number of subjects: 0
Study: 17785973

Group type: EXPERIMENTAL
Intervention: Intermittent infusion (SI) of piperacillin/sulbactam (4/1 g every 8 h)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Continuous infusion (CI) of piperacillin/sulbactam (8/2 g per 24 h after loading dose)
Number of subjects: 7
Study: 12589521

Group type: EXPERIMENTAL
Intervention: Buspirone (30 mg orally)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pindolol (20 mg orally)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination of buspirone and pindolol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Buspirone (30 mg orally) with Pindolol (20 mg orally)
Number of subjects: 14
Study: 10783215

Group type: EXPERIMENTAL
Intervention: SAK42D 15 mg
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: SAK42D 30 mg
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: SAK42D 45 mg
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: SAK42D
Number of subjects: 82
Study: 9816275

Group type: EXPERIMENTAL
Intervention: PALA 125 mg/m2
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: PALA 250 mg/m2
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: PALA 500 mg/m2
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: PALA 1000 mg/m2
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 5-FU 400 mg/m2
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: DP 50 mg/m2
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 5-FU dose escalation
Number of subjects: 88
Study: 1576631

Group type: EXPERIMENTAL
Intervention: imipenem-cilastatin (I-C)
Number of subjects: 94

Group type: COMPARATOR
Intervention: clindamycin+gentamicin (C+G)
Number of subjects: 94
Study: 3930257

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 6
Study: 2829267

Group type: EXPERIMENTAL
Intervention: ZK 93,426 (0.01 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZK 93,426 (0.04 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30475969

Group type: EXPERIMENTAL
Intervention: 1.5 g protein · kg‐1 · d‐1
Number of subjects: 120

Group type: COMPARATOR
Intervention: 0.8 g protein · kg‐1 · d‐1
Number of subjects: 120
Study: 28222641

Group type: EXPERIMENTAL
Intervention: Rapid genotyping-guided treatment (GG)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard treatment (SG)
Number of subjects: 132
Study: 26135562

Group type: EXPERIMENTAL
Intervention: ivacaftor (150 mg)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 23908481

Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccination
Number of subjects: 773
Study: 20394809

Group type: EXPERIMENTAL
Intervention: MS-DMH (dimenhydrinate)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: MS-Scop (scopolamine)
Number of subjects: 9

Group type: COMPARATOR
Intervention: MS-CN (control, no medication, MS provocation)
Number of subjects: 9

Group type: COMPARATOR
Intervention: MS-P (placebo)
Number of subjects: 9

Group type: COMPARATOR
Intervention: CN (control, no medication, no MS provocation)
Number of subjects: 9

Group type: COMPARATOR
Intervention: MS-CN, MS-P
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: MS-DMH
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: MS-Scop
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 9
Study: 19042267

Group type: EXPERIMENTAL
Intervention: Support group (six meetings over 3 months)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Exercises through biofeedback
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study: 16507196

Group type: EXPERIMENTAL
Intervention: prilocaine 1% 40 mL (G1)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: prilocaine 1% 30 mL and ropivacaine 0.75% 10 mL (G2)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: prilocaine 1% 20 mL and ropivacaine 0.75% 20 mL (G3)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.75% 40 mL (G4)
Number of subjects: 96
Study: 14645194

Group type: EXPERIMENTAL
Intervention: 17beta-E(2) (4 mg/day) from day 20 until next cycle day 2
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no E(2) pre-treatment)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 17beta-E(2) (4 mg/day)
Number of subjects: 90
Study: 11012871

Group type: EXPERIMENTAL
Intervention: Dental appliance
Number of subjects: 88

Group type: COMPARATOR
Intervention: UPPP
Number of subjects: 88
Study: 8622848

Group type: EXPERIMENTAL
Intervention: Holmium:YAG laser treatment
Number of subjects: 320

Group type: COMPARATOR
Intervention: Conventional mechanical methods
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Holmium:YAG laser
Number of subjects: 320
Study: 1468241

Group type: EXPERIMENTAL
Intervention: Audax ear drops
Number of subjects: 36

Group type: COMPARATOR
Intervention: Earex ear drops
Number of subjects: 36
Study: 6693582

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 15

Group type: COMPARATOR
Intervention: N-desmethylimipramine
Number of subjects: 15
Study: 30911578

Group type: EXPERIMENTAL
Intervention: IFN‐γ 1b
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 30643809

Group type: EXPERIMENTAL
Intervention: Hepatitis B virus (HBV) infection screening
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Hepatitis C virus (HCV) infection screening
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Sociodemographic data collection and risk factor analysis
Number of subjects: 421
Study: 27439894

Group type: EXPERIMENTAL
Intervention: Cabozantinib and gemcitabine
Number of subjects: 12
Study: 24742939

Group type: EXPERIMENTAL
Intervention: Home-based constraint induced therapy (CIT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Traditional rehabilitation (TR)
Number of subjects: 45
Study: 22460474

Group type: EXPERIMENTAL
Intervention: Whey protein (PRO, n = 17)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (PLA, n = 16)
Number of subjects: 33
Study: 21179731

Group type: EXPERIMENTAL
Intervention: Auricular acupoint pressing (AAP) with Vaccaria seed before operation and local analgesia on affected limb after operation.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Auricular acupoint pressing (AAP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (standard care with celecoxib and local analgesia)
Number of subjects: 60
Study: 18630766

Group type: EXPERIMENTAL
Intervention: Bilateral single-site thoracic paravertebral block with 25 mL of bupivacaine 0.25% with epinephrine 1:200.000
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (25 mL of 0.9% NaCl)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bilateral single-site thoracic paravertebral block
Number of subjects: 24
Study: 16143747

Group type: EXPERIMENTAL
Intervention: Pressure-regulated volume control (PRVC)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation (SIMV)
Number of subjects: 212
Study: 11812424

Group type: EXPERIMENTAL
Intervention: 500 ml of water orally administered 30 minutes before verteporfin infusion
Number of subjects: 250

Group type: COMPARATOR
Intervention: No hydration before therapy
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Total patients
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Back pain
Number of subjects: 250
Study: 11143847

Group type: EXPERIMENTAL
Intervention: External radiotherapy 40 Gy/17 F/3.2 weeks
Number of subjects: 108

Group type: COMPARATOR
Intervention: External radiotherapy 45 Gy/20 F/4 weeks
Number of subjects: 108
Study: 8843206

Group type: EXPERIMENTAL
Intervention: Baseline HIV-1 RNA level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50% reduction in HIV-1 RNA level
Number of subjects: 0
Study: 1600686

Group type: EXPERIMENTAL
Intervention: Verapamil hydrochloride extended-release pellet-filled capsule (240 mg) sprinkled on applesauce
Number of subjects: 32

Group type: COMPARATOR
Intervention: Verapamil hydrochloride extended-release pellet-filled capsule swallowed intact
Number of subjects: 32
Study: 3902237

Group type: EXPERIMENTAL
Intervention: ibuprofen-codeine phosphate combination
Number of subjects: 113

Group type: COMPARATOR
Intervention: codeine phosphate
Number of subjects: 113

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 113
Study: 31125916

Group type: EXPERIMENTAL
Intervention: Active intervention (cognitive/affective computerized training) in chronic PTSD (N = 48)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control intervention (engaging computer games) in chronic PTSD (N = 36)
Number of subjects: 164